President Obama’s 1-million-person health study kicks off with five recruitment centers
By Jocelyn Kaiser,
Science Magazine
| 07. 07. 2016
President Barack Obama’s ambitious 1-million-person personalized medicine study began to take shape this week with the announcement of four medical centers that will recruit volunteers starting this fall. A fifth center aims to sign up 350,000 participants by blasting the general public with ads coming soon to your web browser or mobile phone.
The White House’s announcement yesterday of $55 million in awards from the National Institutes of Health (NIH) fires the starting gun for the Precision Medicine Initiative (PMI) Cohort Program. The plan is to recruit 1 million or more people who are willing to share their health and genetic information over many years to help researchers develop individualized treatments. Other countries have similar studies underway, but the U.S. version aims to be larger, more diverse, and more patient-centric—participants will help shape the study and be able to see their data. NIH Director Francis Collins calls it “the largest, most ambitious research project of this sort ever undertaken.”
President Obama, who first announced the PMI in January 2015, writes today in The Boston Globe that “the ensuing breakthroughs” from...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
